Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2423-2430

  Ma, Gang ^a   Pan, Yixia ^b   Zhou, Can ^a   Sun, Ruifang ^a   Bai, Jingjing ^c   Liu, Peijun ^a   Ren, Yu ^a   He, Jianjun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NORTHWEST WOMEN S AND CHILDREN S HOSPITAL   (China)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Cell apoptosis; JUN NH2 terminal kinases; MCF7 cells; Mitogen activated protein kinase phosphatase 1; Tamoxifen resistance

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SMALL INTERFERING RNA; TAMOXIFEN; TRIPTOLIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DUSP1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CLONE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; WESTERN BLOTTING; DRUG RESISTANCE; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; TAMOXIFEN; UP-REGULATION;

EID: 84941945222     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4244     Document Type: Article

References (34)

1. Cancer Genome Atlas N; Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
2. Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247, 2011.
3. Osborne CK and Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
4. Riggins RB, Schrecengost RS, Guerrero MS and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett 256: 1-24, 2007.
5. García-Becerra R, Santos N, Díaz L and Camacho J: Mechanisms of resistance to endocrine therapy in breast cancer: Focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14: 108-145, 2012.
6. Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
7. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM and Nicholson RI: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96: 131-146, 2006.
8. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476, 2005.
9. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA and Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7: 351-359, 1996.
10. Mandlekar S, Yu R, Tan TH and Kong AN: Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60: 5995-6000, 2000.
11. Theodosiou A and Ashworth A: MAP kinase phosphatases. Genome Biol 3: S3009, 2002.
12. Camps M, Nichols A and Arkinstall S: Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB J 14: 6-16, 2000.
13. Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK and Bennett AM: Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab 4: 61-73, 2006.
14. Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, Baliga RS, Meng X, Smith CV, Bauer JA, et al: MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 203: 131-140, 2006.
15. Wancket LM, Frazier WJ and Liu Y: Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci 90: 237-248, 2012.
16. Li M, Zhou JY, Ge Y, Matherly LH and Wu GS: The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 278: 41059-41068, 2003.
17. Sánchez-Pérez I, Martínez-Gomariz M, Williams D, Keyse SM and Perona R: CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19: 5142-5152, 2000.
18. Wang Z, Xu J, Zhou JY, Liu Y and Wu GS: Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res 66: 8870-8877, 2006.
19. Small GW, Shi YY, Higgins LS and Orlowski RZ: Mitogenactivated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67: 4459-4466, 2007.
20. Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu GS and Ravindranath Y: High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma. Pediatr Blood Cancer 51: 754-759, 2008.
21. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME and Clarke R: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993.
22. Takeuchi K, Shin-ya T, Nishio K and Ito F: Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. FEBS J 276: 1255-1265, 2009.
23. Mandlekar S and Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6: 469-477, 2001.
24. Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S and Davydov M: Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev 6: e15, 2012.
25. Madeo A, Vinciguerra M, Lappano R, Galgani M, Gasperi-Campani A, Maggiolini M and Musti AM: c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 29: 978-991, 2010.
26. Wang N, Li Z, Tian F, Feng Y, Huang J, Li C and Xie F: PKCα inhibited apoptosis by decreasing the activity of JNK in MCF-7/ADR cells. Exp Toxicol Pathol 64: 459-464, 2012.
27. Chen P, Li J, Barnes J, Kokkonen GC, Lee JC and Liu Y: Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 169: 6408-6416, 2002.
28. Zhao Q, Shepherd EG, Manson ME, Nelin LD, Sorokin A and Liu Y: The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: Attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 280: 8101-8108, 2005.
29. Obrero M, Yu DV and Shapiro DJ: Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 277: 45695-45703, 2002.
30. Wang HY, Cheng Z and Malbon CC: Overexpression of mitogenactivated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191: 229-237, 2003.
31. Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, et al: Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 15: 3530-3539, 2009.
32. Wang J, Zhou JY and Wu GS: ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67: 11933-11941, 2007.
33. Rabenoelina F, Semlali A, Duchesne MJ, Freiss G, Pons M and Badia E: Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade. Int J Cancer 98: 698-706, 2002.
34. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM and El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66: 3903-3911, 2006.